Bromhexine
Identification
- Name
- Bromhexine
- Accession Number
- DB09019
- Description
Bromhexine is an expectorant/mucolytic agent. Bromhexine is not available in the United States. It is marketed under the trade name Bisolvon(R) in Germany, England, Belgium, France, Italy, Netherlands, Norway, Sweden, Australia, and South Africa.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Bromhexine (DB09019)
- Weight
- Average: 376.13
Monoisotopic: 373.999323944 - Chemical Formula
- C14H20Br2N2
- Synonyms
- 3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine
- Bromexina
- Bromhexina
- Bromhexine
- Bromhexinum
- N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine
- External IDs
- NA 274
Pharmacology
- Indication
- Not Available
- Associated Therapies
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Bromhexine hydrochloride YC2ZOM3Z8V 611-75-6 UCDKONUHZNTQPY-UHFFFAOYSA-N - International/Other Brands
- Amiorel (Boehringer Ingelheim) / Bisolmed (Boehringer Ingelheim) / Bisolvon (Boehringer Ingelheim) / Bisolvon Chesty (Boehringer Ingelheim) / Fluibron
Categories
- ATC Codes
- R05CB02 — Bromhexine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenylmethylamines
- Direct Parent
- Phenylmethylamines
- Alternative Parents
- Benzylamines / 2-bromoanilines / Cyclohexylamines / Bromobenzenes / Aralkylamines / Aryl bromides / Trialkylamines / Primary amines / Organopnictogen compounds / Organobromides show 1 more
- Substituents
- 2-bromoaniline / Amine / Aniline or substituted anilines / Aralkylamine / Aromatic homomonocyclic compound / Aryl bromide / Aryl halide / Benzylamine / Bromobenzene / Cyclohexylamine show 11 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- organobromine compound, tertiary amino compound, substituted aniline (CHEBI:77032)
Chemical Identifiers
- UNII
- Q1J152VB1P
- CAS number
- 3572-43-8
- InChI Key
- OJGDCBLYJGHCIH-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3
- IUPAC Name
- 2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline
- SMILES
- CN(CC1=CC(Br)=CC(Br)=C1N)C1CCCCC1
References
- Synthesis Reference
U.S. Patent 3,336,308.
- General References
- Not Available
- External Links
- KEGG Drug
- D07542
- PubChem Compound
- 2442
- PubChem Substance
- 310264976
- ChemSpider
- 2348
- BindingDB
- 50239965
- 1753
- ChEBI
- 77032
- ChEMBL
- CHEMBL253376
- ZINC
- ZINC000000608220
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Bromhexine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Increased Risk of SARS-CoV-2 Infection / Novel Coronavirus Infectious Disease (COVID-19) 1 4 Recruiting Treatment Novel Coronavirus Infectious Disease (COVID-19) 1 3 Recruiting Treatment Abnormal Mucus Secretions / Respiratory Tract Diseases 1 3 Recruiting Treatment COVID 19 / Novel Coronavirus Infectious Disease (COVID-19) 1 0 Enrolling by Invitation Prevention Antimalarials / Antirheumatic Agents / Enzyme Inhibitors / Hydroxychloroquine / Novel Coronavirus Infectious Disease (COVID-19) 1 Not Available Active Not Recruiting Treatment Novel Coronavirus Infectious Disease (COVID-19) / Novel Coronavirus Pneumonia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral 8 mg Granule 8 MG Injection Injection, solution 4 MG/2ML Solution Oral 2 MG/ML Suppository 16 MG Suppository 8 MG Suppository Rectal 8 mg Syrup 4 MG/5ML Syrup 8 MG/5ML Syrup Oral 8 mg/5ml Tablet 8 MG Tablet, soluble 8 MG Solution Oral 8 MG/5ML Tablet 8 mg/1 Solution Oral 80 mg Syrup Oral 4 mg/5ml Syrup 200 ml Tablet, sugar coated Oral 8 mg/1 Tablet 12 MG Solution Oral 12 MG/ML Solution Oral 8 MG/ML Syrup Oral 0.16 g Syrup Oral 0.08 g Powder Not applicable 1000 g/1000g Solution Oral Tablet 4 mg Tablet, coated Oral 4 mg Injection, solution 2 mg/1mL Solution Oral 4 mg/5mL Syrup 100 ml Powder Capsule 8 mg Syrup Oral 0.04 g Tablet Syrup Oral Elixir Capsule, liquid filled Oral 8 mg Solution / drops Oral 4 mg/5mL Syrup 2 mg/5mL Solution Syrup Oral 80 mg Syrup Oral 40 mg Solution Oral 0.16 g Syrup Oral 160 mg Solution Oral 0.08 g Tablet, film coated Oral Solution Oral 0.04 g Tablet Oral 8 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 232-235 U.S. Patent 3,336,308. - Predicted Properties
Property Value Source Water Solubility 0.00362 mg/mL ALOGPS logP 4.08 ALOGPS logP 4.42 ChemAxon logS -5 ALOGPS pKa (Strongest Acidic) 19.89 ChemAxon pKa (Strongest Basic) 9.32 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 29.26 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 85.56 m3·mol-1 ChemAxon Polarizability 32.98 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-03di-0095000000-2c4f15e31beb22fd1178 LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-03di-0090000000-4d3be1605bfa79609959 LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-03di-0090000000-428c05c13a2a9e326945 LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-03di-0390000000-b0ece5d5d6f8b78af198
Drug created on June 24, 2014 10:22 / Updated on June 12, 2020 10:52
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates